Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesSub-license for Hepatitis C drug beneficial for patients: Cipla

SHOW NAMES

Trending Topics

business

Sub-license for Hepatitis C drug beneficial for patients: Cipla

Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.

first published: Jan 21, 2016 11:23 am

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347